Rich, BioCurex still has the Smithline debt (with a lien on all the assets) hanging over its head. A lot of the proceeds of that loan were used to make the monthly payments due Smithline. From last December until May of this year, the monthly payments were not made. Only BioCurex management knows what has happened since May. The successful start-up sales examples you mentioned were quite different than attempting to direct sell RECAF. Microsoft didn't need regulatory approval and there was an existing demand for computer operating systems and software. You didn't need to see a doctor to use Microsoft's products. Before anyone says it, I know, start with dog RECAF first. Even with that, veterinarians will have to be involved and they have to be educated and the dog owner will have to pay for all of this and the subsequent expensive tests to attempt to locate the cancer. This approach, even if successful, will be painfully slow. Meanwhile, all those 175 million additional authorized shares have the possibility of running the stock price down to who knows what low level. kag
